152 related articles for article (PubMed ID: 37592424)
1. Development of a UPLC-MS/MS Assay for the Quantitative Determination of Capecitabine, 5'-deoxy-5-fluorocytidine (5'-dFCR), 5'-deoxy-5-fluorouridine (5'-dFUR), 5'-fluorouracil (5-FU), and α-fluoro-β-alanine (FBAL).
Knikman JE; de Vries N; Rosing H; Cats A; Guchelaar HJ; Beijnen JH
Pharmazie; 2023 Aug; 78(8):107-112. PubMed ID: 37592424
[TBL] [Abstract][Full Text] [Related]
2. Quantitative determination of capecitabine and its six metabolites in human plasma using liquid chromatography coupled to electrospray tandem mass spectrometry.
Deenen MJ; Rosing H; Hillebrand MJ; Schellens JH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Jan; 913-914():30-40. PubMed ID: 23270936
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous determination of capecitabine and its three nucleoside metabolites in human plasma by high performance liquid chromatography-tandem mass spectrometry.
Deng P; Ji C; Dai X; Zhong D; Ding L; Chen X
J Chromatogr B Analyt Technol Biomed Life Sci; 2015 May; 989():71-9. PubMed ID: 25808944
[TBL] [Abstract][Full Text] [Related]
4. A new, validated HPLC-MS/MS method for the simultaneous determination of the anti-cancer agent capecitabine and its metabolites: 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, 5-fluorouracil and 5-fluorodihydrouracil, in human plasma.
Vainchtein LD; Rosing H; Schellens JH; Beijnen JH
Biomed Chromatogr; 2010 Apr; 24(4):374-86. PubMed ID: 19650151
[TBL] [Abstract][Full Text] [Related]
5. Metabolism of capecitabine, an oral fluorouracil prodrug: (19)F NMR studies in animal models and human urine.
Desmoulin F; Gilard V; Malet-Martino M; Martino R
Drug Metab Dispos; 2002 Nov; 30(11):1221-9. PubMed ID: 12386128
[TBL] [Abstract][Full Text] [Related]
6. Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients.
Reigner B; Verweij J; Dirix L; Cassidy J; Twelves C; Allman D; Weidekamm E; Roos B; Banken L; Utoh M; Osterwalder B
Clin Cancer Res; 1998 Apr; 4(4):941-8. PubMed ID: 9563888
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetic analysis of the major metabolites of capecitabine.
Gieschke R; Reigner B; Blesch KS; Steimer JL
J Pharmacokinet Pharmacodyn; 2002 Feb; 29(1):25-47. PubMed ID: 12194534
[TBL] [Abstract][Full Text] [Related]
8. Rapid and simultaneous determination of capecitabine and its metabolites in mouse plasma, mouse serum, and in rabbit bile by high-performance liquid chromatography.
Dhananjeyan MR; Liu J; Bykowski C; Trendel JA; Sarver JG; Ando H; Erhardt PW
J Chromatogr A; 2007 Jan; 1138(1-2):101-8. PubMed ID: 17070825
[TBL] [Abstract][Full Text] [Related]
9. Bioactivation of capecitabine in human liver: involvement of the cytosolic enzyme on 5'-deoxy-5-fluorocytidine formation.
Tabata T; Katoh M; Tokudome S; Hosakawa M; Chiba K; Nakajima M; Yokoi T
Drug Metab Dispos; 2004 Jul; 32(7):762-7. PubMed ID: 15205393
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer.
Reigner B; Watanabe T; Schüller J; Lucraft H; Sasaki Y; Bridgewater J; Saeki T; McAleer J; Kuranami M; Poole C; Kimura M; Monkhouse J; Yorulmaz C; Weidekamm E; Grange S
Cancer Chemother Pharmacol; 2003 Sep; 52(3):193-201. PubMed ID: 12783206
[TBL] [Abstract][Full Text] [Related]
11. Measurement of 5- fluorouracil, capecitabine and its metabolite concentrations in blood using volumetric absorptive microsampling technology and LC-MS/MS.
Radovanovic M; Schneider JJ; Shafiei M; Martin JH; Galettis P
J Chromatogr B Analyt Technol Biomed Life Sci; 2022 Jan; 1188():123075. PubMed ID: 34891049
[TBL] [Abstract][Full Text] [Related]
12. Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients.
Poole C; Gardiner J; Twelves C; Johnston P; Harper P; Cassidy J; Monkhouse J; Banken L; Weidekamm E; Reigner B
Cancer Chemother Pharmacol; 2002 Mar; 49(3):225-34. PubMed ID: 11935215
[TBL] [Abstract][Full Text] [Related]
13. Correlation Between the Metabolic Conversion of a Capecitabine Metabolite, 5'-Deoxy-5-fluorocytidine, and Creatinine Clearance.
Inaishi T; Fujita KI; Matsumoto N; Shimokata T; Maeda O; Kikumori T; Hattori N; Nakayama G; Ando Y
In Vivo; 2020; 34(6):3539-3544. PubMed ID: 33144465
[TBL] [Abstract][Full Text] [Related]
14. Lack of contribution of dihydrofluorouracil and alpha-fluoro-beta-alanine to the cytotoxicity of 5'-deoxy-5-fluorouridine on human keratinocytes.
Fischel JL; Formento P; Ciccolini J; Etienne-Grimaldi MC; Milano G
Anticancer Drugs; 2004 Nov; 15(10):969-74. PubMed ID: 15514566
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of Capecitabine and Four Metabolites in a Heterogeneous Population of Cancer Patients: A Comprehensive Analysis.
Jacobs BAW; Deenen MJ; Joerger M; Rosing H; de Vries N; Meulendijks D; Cats A; Beijnen JH; Schellens JHM; Huitema ADR
CPT Pharmacometrics Syst Pharmacol; 2019 Dec; 8(12):940-950. PubMed ID: 31652031
[TBL] [Abstract][Full Text] [Related]
16. Development of a sensitive and selective LC-MS/MS method for the determination of alpha-fluoro-beta-alanine, 5-fluorouracil and capecitabine in human plasma.
Licea-Perez H; Wang S; Bowen C
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Apr; 877(11-12):1040-6. PubMed ID: 19285927
[TBL] [Abstract][Full Text] [Related]
17. Development and validation of a rapid and sensitive UPLC-MS/MS method for determination of uracil and dihydrouracil in human plasma.
Jacobs BA; Rosing H; de Vries N; Meulendijks D; Henricks LM; Schellens JH; Beijnen JH
J Pharm Biomed Anal; 2016 Jul; 126():75-82. PubMed ID: 27179185
[TBL] [Abstract][Full Text] [Related]
18. Validation of a simple assay for the quantification of the capecitabine metabolites 5'-DFCR and 5'-DFUR for drug monitoring in patients receiving outpatient chemotherapy.
Buchner P; Mihola E; Sahmanovic A; Steininger T; Dittrich C; Czejka M
Anticancer Res; 2013 Mar; 33(3):881-6. PubMed ID: 23482757
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients.
Gieschke R; Burger HU; Reigner B; Blesch KS; Steimer JL
Br J Clin Pharmacol; 2003 Mar; 55(3):252-63. PubMed ID: 12630975
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic modelling of 5-FU production from capecitabine--a population study in 40 adult patients with metastatic cancer.
Urien S; Rezaí K; Lokiec F
J Pharmacokinet Pharmacodyn; 2005 Dec; 32(5-6):817-33. PubMed ID: 16284918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
